GlassScriptPhysician profile
Karina Hooper
NPI 1538105069
$3,417.60
in general payments reported to CMS, 2019-2025
22 companies · $1,274 in 2025
The $1,274 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.23 · 2022: $389 · 2023: $794 · 2024: $923 · 2025: $1,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,990.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,712.27 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $259.73 | 2024-2025 | Zenpep |
| Janssen Biotech, INC. | $232.21 | 2024-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.56 | 2023-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $138.51 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $130.06 | 2023-2024 | Gattex, Eohilia |
| Vivus LLC | $127.16 | 2023-2025 | Pancreaze, Qsymia |
| Regeneron Healthcare Solutions, INC. | $99.03 | 2023-2025 | Dupixent |
| Pfizer INC. | $96.66 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $80.15 | 2023-2024 | Linzess |
| Exact Sciences Corporation | $66.49 | 2023-2024 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $52.05 | 2024 | |
| Novo Nordisk INC | $48.59 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $39.51 | 2022-2023 | Dificid |
| Braintree Laboratories, INC. | $36.80 | 2022-2023 | Sutab, Suflave |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $29.38 | 2025 | Givlaari |
| Axonics, INC. | $24.14 | 2023 | Axonics |
| Ipsen Biopharmaceuticals, INC | $23.94 | 2024 | Iqirvo |
| Celltrion USA INC. | $20.51 | 2025 | Vegzelma |
| Lilly USA, LLC | $20.07 | 2025 | Zepbound |
| Laborie Medical Technologies Corp. | $15.87 | 2024 | Urgent PC Neuromodulation System |
| Boston Scientific Corporation | $14.91 | 2025 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karina Hooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.